Admera Health Expands Liquid Biopsy Offering to Include Detection of Copy Number Variation and Microsatellite Instability

South Plainfield, NJ – October 23, 2018 – At CAP18, in Chicago, IL, Admera Health (www.admerahealth.com), unveiled an expansion to its next generation sequencing (NGS) based LiquidGx™ test for solid tumor-targeted therapy selection from a blood sample. This extended version increases the utility of the assay by raising the number of genes to 17 and including detection of copy number variation and microsatellite instability.

LiquidGx™ utilizes a proprietary enrichment technique to detect circulating tumor DNA (ctDNA) at low levels. The original NGS panel was a 10-gene assay covering single nucleotide variants (SNV), insertions and deletions (indels), and fusions with a limit-of-detection of 0.1% and a turnaround time of three to five days. The 17-gene panel will maintain the previous limit-of-detection and turnaround time for SNVs, indels, and fusions; while, MSI and CNV detection will have a limit-of-detection of 2% and 2.5 gene copies respectively. In addition to the NGS panel, qPCR offerings for ALK, BRAF, EGFR, and KRAS are also available with a limit-of-detection of 0.01% and a turnaround time of fewer than three days.

“We view liquid biopsy as a component of solid tumor profiling that is synergistic with other techniques and something that should routinely be included within an oncologist’s workflow. This is especially the case when tissue is unavailable or dangerous to extract. These benefits were outlined in a recent JAMA Oncology paper authored by a group out of UPenn,” stated Guanghui Hu, Ph.D., President, and CEO of Admera Health. Hu continued, “Our belief is even firmer now that LiquidGx™ testing includes MSI stability and can provide drug recommendations that include anti-PD1 therapy. While this is an impressive development, the addition of CNV detection is something that should not be overlooked due to associated targeted drugs.”

In addition to liquid biopsy, Admera Health’s Oncology Test Portfolio includes NGS panels for solid tumor profiling from tissue (OncoGxSelect™ and OncoGxOne™) and pharmacogenomics for supportive care and chemotherapeutic selection (PGxOnco™).

“Admera’s Oncology Test Portfolio is unique in that we have genomics solutions that span the continuum of cancer patient care with strong capabilities in liquid biopsy, NGS based solid tumor profiling, and pharmacogenomics. Whether it is non-invasive cancer testing, helping to alleviate chemotherapy-induced nausea and vomiting, or identifying the right clinical trial, Admera is committed to helping physicians improve patient outcomes,” explained Brady Millican, Vice President of Business Development.

About Admera Health

Admera Health is a CLIA-certified and CAP-accredited advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing, digital health, and providing research use only services. Research and development efforts are dedicated to developing cutting-edge diagnostics that span the continuum of care. Utilizing next generation technology platforms and advanced bioinformatics, Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions. It is our mission to deliver transformative, valuable solutions to patients, physicians, and clinical researchers. We are committed to improving the health and well-being of our global community through the direct delivery of personalized, medically actionable results.

Admera Health Contact:

Brady Millican,
VP Business Development
908-222-0533
brady.millican@admerahealth.com